Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

363 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical features of LRP4/agrin-antibody-positive myasthenia gravis: A multicenter study.
Rivner MH, Quarles BM, Pan JX, Yu Z, Howard JF Jr, Corse A, Dimachkie MM, Jackson C, Vu T, Small G, Lisak RP, Belsh J, Lee I, Nowak RJ, Baute V, Scelsa S, Fernandes JA, Simmons Z, Swenson A, Barohn R, Sanka RB, Gooch C, Ubogu E, Caress J, Pasnoor M, Xu H, Mei L. Rivner MH, et al. Among authors: lisak rp. Muscle Nerve. 2020 Sep;62(3):333-343. doi: 10.1002/mus.26985. Epub 2020 Jun 10. Muscle Nerve. 2020. PMID: 32483837 Free PMC article.
Autoantibodies to agrin in myasthenia gravis patients.
Zhang B, Shen C, Bealmear B, Ragheb S, Xiong WC, Lewis RA, Lisak RP, Mei L. Zhang B, et al. Among authors: lisak rp. PLoS One. 2014 Mar 14;9(3):e91816. doi: 10.1371/journal.pone.0091816. eCollection 2014. PLoS One. 2014. PMID: 24632822 Free PMC article.
Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis: Results of a Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial.
Howard JF Jr, Nowak RJ, Wolfe GI, Freimer ML, Vu TH, Hinton JL, Benatar M, Duda PW, MacDougall JE, Farzaneh-Far R, Kaminski HJ; Zilucoplan MG Study Group; Barohn R, Dimachkie M, Pasnoor M, Farmakidis C, Liu T, Colgan S, Benatar MG, Bertorini T, Pillai R, Henegar R, Bromberg M, Gibson S, Janecki T, Freimer M, Elsheikh B, Matisak P, Genge A, Guidon A, David W, Habib AA, Mathew V, Mozaffar T, Hinton JL, Hewitt W, Barnett D, Sullivan P, Ho D, Howard JF Jr, Traub RE, Chopra M, Kaminski HJ, Aly R, Bayat E, Abu-Rub M, Khan S, Lange D, Holzberg S, Khatri B, Lindman E, Olapo T, Sershon LM, Lisak RP, Bernitsas E, Jia K, Malik R, Lewis-Collins TD, Nicolle M, Nowak RJ, Sharma A, Roy B, Nye J, Pulley M, Berger A, Shabbir Y, Sachdev A, Patterson K, Siddiqi Z, Sivak M, Bratton J, Small G, Kohli A, Fetter M, Vu T, Lam L, Harvey B, Wolfe GI, Silvestri N, Patrick K, Zakalik K, Duda PW, MacDougall J, Farzaneh-Far R, Pontius A, Hoarty M. Howard JF Jr, et al. Among authors: lisak rp. JAMA Neurol. 2020 May 1;77(5):582-592. doi: 10.1001/jamaneurol.2019.5125. JAMA Neurol. 2020. PMID: 32065623 Free PMC article. Clinical Trial.
LRP4 antibody testing in myasthenia gravis.
Racke MK, Batish SD, Lisak RP, Barohn RJ. Racke MK, et al. Among authors: lisak rp. J Neuroimmunol. 2022 Oct 15;371:577949. doi: 10.1016/j.jneuroim.2022.577949. Epub 2022 Aug 12. J Neuroimmunol. 2022. PMID: 35973344 No abstract available.
Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial.
Howard JF Jr, Bril V, Vu T, Karam C, Peric S, Margania T, Murai H, Bilinska M, Shakarishvili R, Smilowski M, Guglietta A, Ulrichts P, Vangeneugden T, Utsugisawa K, Verschuuren J, Mantegazza R; ADAPT Investigator Study Group. Howard JF Jr, et al. Lancet Neurol. 2021 Jul;20(7):526-536. doi: 10.1016/S1474-4422(21)00159-9. Lancet Neurol. 2021. PMID: 34146511 Clinical Trial.
The thymus and myasthenia gravis.
Ragheb S, Lisak RP. Ragheb S, et al. Among authors: lisak rp. Chest Surg Clin N Am. 2001 May;11(2):311-27, x. Chest Surg Clin N Am. 2001. PMID: 11413758 Review.
363 results